Study of MT-201 in Healthy Volunteers
This study is testing a drug called MT-201 for the first time in people. It will look at how safe MT-201 is, how well your body handles it (tolerability), how your body processes it (pharmacokinetics or PK), and if your immune system reacts to it (immunogenicity). You might receive MT-201 or a placebo (an inactive substance). We are looking for healthy volunteers between 19 and 55 years old. Women must be past menopause or surgically sterile. The main goal is to track any side effects over about 40 weeks. The study plans to enroll 72 participants, but its current status is unclear.
- Study design
- This is a first-in-human study that will involve 72 healthy participants. It will test single and multiple doses of MT-201 against a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 40 weeks to monitor for side effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with non-SAEs and SAESUp to 40 weeks
Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.